超肺保护性通气与重症ARDS患者接受静脉-静脉体外膜氧合时的生物创伤:一项随机对照研究
这项前瞻性随机对照研究将接受vv-ECMO的重症ARDS患者随机分为超肺保护性通气组(潮气量1-2 mL/kg预测体重、低呼吸频率5-10次/分、呼气末跨肺压为正、16小时俯卧位)与肺保护性通气组(遵循EOLIA试验ECMO组方案),干预48小时。主要终点为随机化48小时后肺泡灌洗液中白介素-1β、白介素-6、白介素-8、表面活性蛋白D浓度及血清晚期糖基化终末产物和血管生成素-2血浓度。纳入39例后因无效而停止入组。超肺保护性通气组潮气量、呼吸频率、分钟通气量、平台压和机械功率均显著更低,但预设生物标志物浓度在48小时后两组间均无差异。超肺保护性通气组60天死亡率有升高趋势(45% vs 17%,p=0.06)。作者认为该通气策略对临床结局的影响需进一步研究。
要点
- 超肺保护性通气方案:潮气量1-2 mL/kg预测体重、呼吸频率5-10次/分、呼气末跨肺压为正、16小时俯卧位,持续48小时。
- 对照组遵循EOLIA试验ECMO组的肺保护性通气方案。
- 超肺保护性通气组潮气量、呼吸频率、分钟通气量、平台压和机械功率均显著低于对照组。
- 随机化48小时后,白介素-1β、白介素-6、白介素-8、表面活性蛋白D肺泡浓度及血清晚期糖基化终末产物、血管生成素-2血浓度两组间均无差异。
- 超肺保护性通气组60天死亡率有升高趋势:45% vs 17%(p=0.06)。
适用人群与场景
- 接受静脉-静脉体外膜氧合(vv-ECMO)支持的重症急性呼吸窘迫综合征(ARDS)患者。
处置流程与药物剂量
- 超肺保护性通气组:持续48小时,潮气量1-2 mL/kg预测体重、呼吸频率5-10次/分、呼气末跨肺压为正、16小时俯卧位。
- 对照组:遵循EOLIA试验ECMO组的肺保护性通气方案。
研究设计与关键结果
- 研究类型:前瞻性随机对照研究;纳入39例后因无效停止入组。
- 主要终点:随机化48小时后肺泡白介素-1β、白介素-6、白介素-8、表面活性蛋白D浓度及血清晚期糖基化终末产物、血管生成素-2血浓度,两组间均无差异。
- 超肺保护性通气组潮气量、呼吸频率、分钟通气量、平台压和机械功率均显著低于对照组。
- 60天死亡率:超肺保护性通气组45% vs 对照组17%,p=0.06。
证据类型、等级与局限
- 证据类型:前瞻性随机对照研究。
- 局限:纳入39例后因无效停止入组;作者指出该通气策略对临床结局的影响需进一步研究。
对床旁实践的改变
- 在vv-ECMO支持的重症ARDS患者中,48小时超肺保护性通气虽显著降低机械功率,但未减少生物创伤;作者认为该通气策略对临床结局的影响需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ultra-lung-protective ventilation may be useful during veno-venous extracorporeal membrane oxygenation (vv-ECMO) for severe acute respiratory distress syndrome (ARDS) to minimize ventilator-induced lung injury and to facilitate lung recovery. The objective was to compare pulmonary and systemic biotrauma evaluated by numerous biomarkers of inflammation, epithelial, endothelial injuries, and lung repair according to two ventilator strategies on vv-ECMO.
METHODS: This is a prospective randomized controlled study. Patients were randomized to receive during 48 h either ultra-lung-protective ventilation combining very low tidal volume (1-2 mL/kg of predicted body weight), low respiratory rate (5-10 cycles per minute), positive expiratory transpulmonary pressure, and 16 h of prone position or lung-protective-ventilation which followed the ECMO arm of the EOLIA trial (control group).
RESULTS: The primary outcome was the alveolar concentrations of interleukin-1-beta, interleukin-6, interleukin-8, surfactant protein D, and blood concentrations of serum advanced glycation end products and angiopoietin-2 48 h after randomization. Enrollment was stopped for futility after the inclusion of 39 patients. Tidal volume, respiratory rate, minute ventilation, plateau pressure, and mechanical power were significantly lower in the ultra-lung-protective group. None of the concentrations of the pre-specified biomarkers differed between the two groups 48 h after randomization. However, a trend to higher 60-day mortality was observed in the ultra-lung-protective group compared to the control group (45 vs 17%, p = 0.06).
CONCLUSIONS: Despite a significant reduction in the mechanical power, ultra-lung-protective ventilation during 48 h did not reduce biotrauma in patients with vv-ECMO-supported ARDS. The impact of this ventilation strategy on clinical outcomes warrants further investigation. Trial registration Clinical trial registered with www.
CLINICALTRIALS: gov ( NCT03918603 ). Registered 17 April 2019.
参考来源
- Guervilly C, Fournier T, Chommeloux J, et al. Ultra-lung-protective ventilation and biotrauma in severe ARDS patients on veno-venous extracorporeal membrane oxygenation: a randomized controlled study. Crit Care. 2022. PMID: 36510324. doi:10.1186/s13054-022-04272-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。